NCT04653467View on ClinicalTrials.gov

A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

November 6, 2020

Primary Completion Date

January 10, 2022

Study Completion Date

January 10, 2022

Conditions
Healthy
Interventions
DRUG

GLPG4399 oral suspension

GLPG4399 for oral administration

DRUG

GLPG4399 capsules

GLPG4399 for oral administration

DRUG

Placebo

Placebo oral suspension

Trial Locations (1)

H3P 3E5

Altasciences Montreal, Mount Royal

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT04653467 - A Study to Evaluate How Well Single and Multiple Doses of GLPG4399 Are Tolerated in Healthy, Adult Subjects | Biotech Hunter | Biotech Hunter